Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C47H80O18 |
| Molecular Weight | 933.1273 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 25 / 25 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O)C(C)(C)[C@]4([H])[C@H](C[C@@]23C)O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])OC[C@@H](O)[C@H](O)[C@H]6O)[C@](C)(CCC=C(C)C)O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O
InChI
InChIKey=LLPWNQMSUYAGQI-OOSPGMBYSA-N
InChI=1S/C47H80O18/c1-21(2)10-9-13-47(8,65-41-37(59)34(56)32(54)26(18-48)62-41)22-11-15-45(6)30(22)23(50)16-28-44(5)14-12-29(52)43(3,4)39(44)25(17-46(28,45)7)61-42-38(35(57)33(55)27(19-49)63-42)64-40-36(58)31(53)24(51)20-60-40/h10,22-42,48-59H,9,11-20H2,1-8H3/t22-,23+,24+,25-,26+,27+,28+,29-,30-,31-,32+,33+,34-,35-,36+,37+,38+,39-,40-,41-,42+,44+,45+,46+,47-/m0/s1
| Molecular Formula | C47H80O18 |
| Molecular Weight | 933.1273 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 25 / 25 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27571993 | https://www.ncbi.nlm.nih.gov/pubmed/25503068 | https://www.ncbi.nlm.nih.gov/pubmed/25203723
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27571993 | https://www.ncbi.nlm.nih.gov/pubmed/25503068 | https://www.ncbi.nlm.nih.gov/pubmed/25203723
Notoginsenoside R1 is a characteristic constituent of Radix notoginseng, a well known herbal medicine widely used in Asian countries for treating microcirculatory disturbance-related diseases, such as diabetic nephropathy, cardiovascular disease, cerebral vascular disease, and liver dysfunction. Notoginsenoside R1 has multiple pharmacologic activities, including cardioprotective, neuroprotective, anti-inflammatory, and anticancer effects. A study on the application of Notoginsenoside R1 in a rat model of diabetic nephropathy indicated that Notoginsenoside R1 ameliorated the glucose-induced impairment of podocyte adhesive capacity and subsequent podocyte depopulation, partly through the upregulation of α3β1 integrin via PI3K-Akt signaling pathway activation.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Notoginsenoside R1 ameliorates podocyte adhesion under diabetic condition through α3β1 integrin upregulation in vitro and in vivo. | 2014 |
|
| Protective effects of panax notoginseng saponins on cardiovascular diseases: a comprehensive overview of experimental studies. | 2014 |
|
| Notoginsenoside R1 attenuates hypoxia and hypercapnia-induced vasoconstriction in isolated rat pulmonary arterial rings by reducing the expression of ERK. | 2014 |
|
| ROCK-dependent ATP5D modulation contributes to the protection of notoginsenoside NR1 against ischemia-reperfusion-induced myocardial injury. | 2014 Dec 15 |
|
| Effects of Astragaloside IV combined with the active components of Panax notoginseng on oxidative stress injury and nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 signaling pathway after cerebral ischemia-reperfusion in mice. | 2014 Oct |
|
| Notoginsenoside R1 attenuates amyloid-β-induced damage in neurons by inhibiting reactive oxygen species and modulating MAPK activation. | 2014 Sep |
|
| Notoginsenoside R1 increases neuronal excitability and ameliorates synaptic and memory dysfunction following amyloid elevation. | 2014 Sep 12 |
|
| Notoginsenoside R1 reduces blood pressure in spontaneously hypertensive rats through a long non-coding RNA AK094457. | 2015 |
|
| Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3. | 2015 Feb |
Patents
Sample Use Guides
Notoginsenoside R1 was administrated orally at doses 5, 10 and 20 mg/kg•day to rats with diabetic nephropathy. Notoginsenoside R1was administered during 16 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: High glucose decreased podocyte adhesive capacity and α3β1 integrin expression, the main podocyte anchoring dimer to the glomerular basement membrane. However, Notoginsenoside R1 ameliorated impaired podocyte adhesive capacity and partially restored α3β1 integrin protein and mRNA expression.
Treatment with 10 and 100 μg/ml of Notoginsenoside R1 for 24 hours significantly increased the adhesion of podocytes to basement membrane protein complex
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:38:45 GMT 2023
by
admin
on
Sat Dec 16 09:38:45 GMT 2023
|
| Record UNII |
Z62692362Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Z62692362Z
Created by
admin on Sat Dec 16 09:38:45 GMT 2023 , Edited by admin on Sat Dec 16 09:38:45 GMT 2023
|
PRIMARY | |||
|
DTXSID101036451
Created by
admin on Sat Dec 16 09:38:45 GMT 2023 , Edited by admin on Sat Dec 16 09:38:45 GMT 2023
|
PRIMARY | |||
|
80418-24-2
Created by
admin on Sat Dec 16 09:38:45 GMT 2023 , Edited by admin on Sat Dec 16 09:38:45 GMT 2023
|
PRIMARY | |||
|
8111
Created by
admin on Sat Dec 16 09:38:45 GMT 2023 , Edited by admin on Sat Dec 16 09:38:45 GMT 2023
|
PRIMARY | |||
|
441934
Created by
admin on Sat Dec 16 09:38:45 GMT 2023 , Edited by admin on Sat Dec 16 09:38:45 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
